Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.35 |
| ▸ | PRKACA | P17612 | 5/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.35 |
| ▸ | PRKACG | P22612 | 4/20 | 0.35 |
| ▸ | PRKACB | P22694 | 4/20 | 0.35 |
| ▸ | PRKCG | P05129 | 4/20 | 0.35 |
| ▸ | PRKCB | P05771 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | PRKCA | P17252 | 4/20 | 0.35 |
| ▸ | PRKCH | P24723 | 4/20 | 0.35 |
| ▸ | PRKCI | P41743 | 4/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006560 | 0.81 | ROCK2 (0.34) | MAPTMAPK1PRKCDPRKACAPRKD3 | |
| SCHEMBL29469895 | 0.81 | ROCK2 (0.50) | MAPTMAPK1PRKCDPRKACAPRKD3 | |
| SCHEMBL31537 | 0.81 | ROCK2 (0.47) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| SCHEMBL2000333 | 0.81 | ROCK2 (0.50) | MAPTMAPK1PRKCDPRKACAPRKD3 | |
| SCHEMBL17228293 | 0.81 | TRPV4 (0.37) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| Hydrochloric Acid SCHEMBL7823569 | 0.80 | ROCK2 (0.33) | MAPTMAPK1PRKCDPRKACAPRKD3 | |
| Bromide SCHEMBL28709695 | 0.80 | ROCK2 (0.46) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| Hydrochloric Acid SCHEMBL999448 | 0.80 | ROCK2 (0.47) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| Iodide SCHEMBL28700199 | 0.80 | ROCK2 (0.46) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| SCHEMBL8762730 | 0.80 | MAPT (0.59) | MAPTMAPK1CYP3A4KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227054-B | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-3877364-B1 | ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11155559-B2 | Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7618984-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1932841-A1 | SULFONAMIDE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| CN-1210521-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO LTD (JP) | 1999-03-10 | — | — | CN | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | PDE6G, PDE3A, PDE5A | MAPT 2566/4885MAPK1 1546/4885PRKCD 2924/4885 |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | AKT1, ROCK1, ROCK2 | MAPT 4573/4885MAPK1 80/4885PRKCD 634/4885 |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | MAPT 1477/4885MAPK1 459/4885PRKCD 235/4885 |
| US-20070179127-A1 | Sulfonamide compound | MYLK, MYLK2, MYLK3 | MAPT 4244/4885MAPK1 182/4885PRKCD 975/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | MAPT 1477/4885MAPK1 459/4885PRKCD 235/4885 |
| US-11155559-B2 | Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity | KCNQ2, KCNQ1, KCNH3 | MAPT 2956/4885MAPK1 476/4885PRKCD 250/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | MAPT 4789/4885MAPK1 180/4885PRKCD 802/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | MAPT 1477/4885MAPK1 459/4885PRKCD 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.